A Multicenter, Open-Label, Phase I/II Study Of EOS884448 In Combination With Standard Of Care And/Or Investigational therapies In participants With Advanced Solid Tumors Read more
A Phase 2 Study Of Erdafitinib In Subjects With Advanced Solid Tumors And Selected FGFR Gene Alterations. Read more
An open-label phase II study to investigate the efficacy, safety, and pharmacokinetics of tirabrutinib in patients with Primary Central Nervous System Lymphoma (PCNSL) Read more
Phase 1b/2, Open-Label Dose Escalation With Expansion Study Of A ACTIVE Investigational Product In Adult Subjects With Relapsed/Refractory Primary Or Secondary Central Nervous System Lymphoma, Followed By A Phase 2 Open-Label Single Dose Level Study Of The Study Drug In Adult Subjects With Relapsed/Refractory Primary Central Nervous System Lymphoma. Read more
Treatment Of Actively Diagnosed Diffuse Anaplastic Wilms Tumors (DAWT) And Relapsed Favorable Histology Wilms Tumors (FHWT) Read more
A Phase 2 Study Of Dabrafenib (NSC# 763760) With Trametinib (NSC# 763093) After Local Irradiation In Actively-Diagnosed BRAF V600-Mutant High-Grade Glioma (HGG) Read more
A Phase 2 Study Of Veliparib (ABT-888) And Local Irradiation, Followed By Maintenance Veliparib And Temozolomide, In Patients With Actively Diagnosed High-Grade Glioma (HGG) Without H3 K27M Or BRAFV600 Mutations Read more
A Phase 3 Randomized Non-Inferiority Study Of Carboplatin And Vincristine Versus Selumetinib (NSC# 748727) In Actively Diagnosed Or Previously Untreated Low-Grade Glioma (LGG) Not Associated With BRAFV600E Mutations Or Systemic Neurofibromatosis Type 1 (NF1) Read more
A Phase 2, Open-Label Study Of Encorafenib + Binimetinib In Patients With BRAFV600E-Mutant Non-Small Cell Lung Cancer Read more
